vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and FRANKLIN STREET PROPERTIES CORP (FSP). Click either name above to swap in a different company.
FRANKLIN STREET PROPERTIES CORP is the larger business by last-quarter revenue ($26.0M vs $21.9M, roughly 1.2× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -28.1%, a 35.3% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -8.2%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -8.7%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
CUE vs FSP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $26.0M |
| Net Profit | $1.6M | $-7.3M |
| Gross Margin | — | 59.4% |
| Operating Margin | 9.0% | -27.9% |
| Net Margin | 7.2% | -28.1% |
| Revenue YoY | 1292.3% | -8.2% |
| Net Profit YoY | 116.7% | 14.1% |
| EPS (diluted) | $0.05 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $26.0M | ||
| Q3 25 | $2.1M | $27.3M | ||
| Q2 25 | $3.0M | $26.7M | ||
| Q1 25 | $421.0K | $27.1M | ||
| Q4 24 | $1.6M | $28.4M | ||
| Q3 24 | $3.3M | $29.7M | ||
| Q2 24 | $2.7M | $30.8M | ||
| Q1 24 | $1.7M | $31.2M |
| Q4 25 | $1.6M | $-7.3M | ||
| Q3 25 | $-7.4M | $-8.3M | ||
| Q2 25 | $-8.5M | $-7.9M | ||
| Q1 25 | $-12.3M | $-21.4M | ||
| Q4 24 | — | $-8.5M | ||
| Q3 24 | $-8.7M | $-15.6M | ||
| Q2 24 | $-10.2M | $-21.0M | ||
| Q1 24 | $-12.3M | $-7.6M |
| Q4 25 | — | 59.4% | ||
| Q3 25 | — | 60.9% | ||
| Q2 25 | — | 59.9% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 59.7% | ||
| Q3 24 | — | 61.0% | ||
| Q2 24 | — | 64.2% | ||
| Q1 24 | — | 64.7% |
| Q4 25 | 9.0% | -27.9% | ||
| Q3 25 | -353.4% | -30.5% | ||
| Q2 25 | -292.3% | -29.2% | ||
| Q1 25 | -2921.4% | -78.9% | ||
| Q4 24 | — | -29.9% | ||
| Q3 24 | -264.2% | -52.4% | ||
| Q2 24 | -390.6% | -68.0% | ||
| Q1 24 | -737.8% | -24.0% |
| Q4 25 | 7.2% | -28.1% | ||
| Q3 25 | -346.6% | -30.5% | ||
| Q2 25 | -287.1% | -29.5% | ||
| Q1 25 | -2911.4% | -79.1% | ||
| Q4 24 | — | -30.0% | ||
| Q3 24 | -259.6% | -52.6% | ||
| Q2 24 | -382.7% | -68.2% | ||
| Q1 24 | -719.1% | -24.2% |
| Q4 25 | $0.05 | $-0.06 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $-0.09 | $-0.08 | ||
| Q1 25 | $-0.17 | $-0.21 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $-0.17 | $-0.15 | ||
| Q2 24 | $-0.20 | $-0.20 | ||
| Q1 24 | $-0.25 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $30.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $607.0M |
| Total Assets | $42.2M | $892.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $30.6M | ||
| Q3 25 | $11.7M | $31.4M | ||
| Q2 25 | $27.5M | $29.4M | ||
| Q1 25 | $13.1M | $30.2M | ||
| Q4 24 | $22.5M | $41.1M | ||
| Q3 24 | $32.4M | $40.9M | ||
| Q2 24 | $30.0M | $30.2M | ||
| Q1 24 | $41.0M | $34.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $607.0M | ||
| Q3 25 | $13.2M | $615.3M | ||
| Q2 25 | $18.2M | $624.7M | ||
| Q1 25 | $6.6M | $633.4M | ||
| Q4 24 | $17.5M | $655.9M | ||
| Q3 24 | $25.4M | $665.4M | ||
| Q2 24 | $21.6M | $682.1M | ||
| Q1 24 | $30.0M | $703.9M |
| Q4 25 | $42.2M | $892.9M | ||
| Q3 25 | $31.6M | $901.0M | ||
| Q2 25 | $40.7M | $903.2M | ||
| Q1 25 | $22.3M | $916.4M | ||
| Q4 24 | $32.2M | $946.9M | ||
| Q3 24 | $44.8M | $981.5M | ||
| Q2 24 | $42.3M | $1.0B | ||
| Q1 24 | $54.0M | $1.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $3.8M |
| Free Cash FlowOCF − Capex | — | $-12.7M |
| FCF MarginFCF / Revenue | — | -48.6% |
| Capex IntensityCapex / Revenue | 0.0% | 63.0% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-25.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $3.8M | ||
| Q3 25 | $-9.0M | $8.3M | ||
| Q2 25 | $-3.4M | $-2.9M | ||
| Q1 25 | $-8.2M | $-5.5M | ||
| Q4 24 | $-36.3M | $9.0M | ||
| Q3 24 | $-7.5M | $14.5M | ||
| Q2 24 | $-10.0M | $-648.0K | ||
| Q1 24 | $-9.8M | $-7.1M |
| Q4 25 | — | $-12.7M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | $-3.4M | $-5.7M | ||
| Q1 25 | $-8.3M | $-9.9M | ||
| Q4 24 | $-36.4M | $-16.2M | ||
| Q3 24 | $-7.5M | $8.6M | ||
| Q2 24 | $-10.0M | $-5.1M | ||
| Q1 24 | $-9.8M | $-15.8M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | -116.5% | -21.5% | ||
| Q1 25 | -1976.7% | -36.7% | ||
| Q4 24 | -2309.3% | -57.2% | ||
| Q3 24 | -225.7% | 29.1% | ||
| Q2 24 | -376.2% | -16.7% | ||
| Q1 24 | -573.0% | -50.8% |
| Q4 25 | 0.0% | 63.0% | ||
| Q3 25 | 0.0% | 19.4% | ||
| Q2 25 | 0.9% | 10.7% | ||
| Q1 25 | 35.6% | 16.4% | ||
| Q4 24 | 4.2% | 88.9% | ||
| Q3 24 | 0.0% | 19.6% | ||
| Q2 24 | 0.4% | 14.6% | ||
| Q1 24 | 3.2% | 28.1% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
FSP
Segment breakdown not available.
